Relacorilant

Major

Relacorilant Acetaminophen And Codeine Capital® & Codeine Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Clindamycin ANTIROBE Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Omeprazole Gastrobim Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Sertraline Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Buprenorphine Belbuca Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Colchicine Colcrys Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Simvastatin Flolipid Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Abemaciclib Verzenio Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Acalabrutinib Calquence Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Alpelisib Piqray Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Apixaban Eliquis Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Apremilast Otezla Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Aripiprazole Injection Abilify Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Asciminib Scemblix Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Atogepant Qulipta Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Avapritinib Ayvakit Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Avatrombopag Doptelet Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Belumosudil Rezurock Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Atorvastatin Atorvaliq Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Abiraterone Abirtega Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Aficamten Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Alfuzosin UroXatral Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Amlodipine Amvaz® Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Avanafil Stendra Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Axitinib Inlyta Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Beclomethasone Nasal Spray Beconase Reduced relacorilant exposure and reduced efficacy of relacorilant, reduced glucocorticoids exposure and reduced efficacy of gluco... Details Relacorilant Beclomethasone Oral Inhalation Beclovent® Reduced relacorilant exposure and reduced efficacy of relacorilant, reduced glucocorticoids exposure and reduced efficacy of gluco... Details Relacorilant Bedaquiline Sirturo Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Bosutinib Bosulif Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Brexpiprazole Rexulti Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Brigatinib Alunbrig Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Budesonide Entocort Reduced relacorilant exposure and reduced efficacy of relacorilant, altered (reduced/increased) glucocorticoids exposure, reduced... Details Relacorilant Budesonide Nasal Spray Rhinocort Reduced relacorilant exposure and reduced efficacy of relacorilant, altered (reduced/increased) glucocorticoids exposure, reduced... Details Relacorilant Budesonide Oral Inhalation Pulmicort Reduced relacorilant exposure and reduced efficacy of relacorilant, altered (reduced/increased) glucocorticoids exposure, reduced... Details Relacorilant Cabozantinib Cabometyx Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Cabozantinib (Thyroid Cancer) Cabometyx Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Capmatinib Tabrecta Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Relacorilant Ciclesonide Nasal Spray Omnaris Reduced relacorilant exposure and reduced efficacy of relacorilant, reduced glucocorticoids exposure and reduced efficacy of gluco... Details Relacorilant Ciclesonide Oral Inhalation Alvesco Reduced relacorilant exposure and reduced efficacy of relacorilant, reduced glucocorticoids exposure and reduced efficacy of gluco... Details Relacorilant Clindamycin Injection ANTIROBE Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details